An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA > 99.9%) Kidney Transplant Patients With Positive Crossmatch Against a Deceased Donor

Sponsored by CTI Clinical Trial and Consulting Services Incorporated